BioSyent Stock

BioSyent Stock-Based Compensation

The Stock-Based Compensation (SBC) of BioSyent (RX.V) as of Aug 22, 2026 is 624,613.00 CAD. In the previous year, Stock-Based Compensation (SBC) was 553,521.00 CAD — a change of 12.84% (higher).

Stock-Based Compensation

624,613.00CAD

YoY

12.84%

Last updated:

Stock-Based Compensation (SBC) of BioSyent is 2026 624,613.00 CAD. Stock-Based Compensation (SBC) of BioSyent was 2025 553,521.00 CAD. It decreases by 12.84% higher compared to the previous year.

The BioSyent Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2018
390,388.00 CAD
Jan 1, 2019
263,245.00 CAD
Jan 1, 2020
266,173.00 CAD
Jan 1, 2021
334,410.00 CAD
Jan 1, 2022
439,671.00 CAD
Jan 1, 2023
513,486.00 CAD
Jan 1, 2024
553,521.00 CAD
Jan 1, 2025
624,613.00 CAD
The BioSyent Stock-Based Compensation history
YEARStock-Based CompensationYoY
624,613.00CAD+12.84%
553,521.00CAD+7.80%
513,486.00CAD+16.79%
439,671.00CAD+31.48%
334,410.00CAD+25.64%
266,173.00CAD+1.11%
263,245.00CAD-32.57%
390,388.00CAD+102.71%
192,581.00CAD-18.22%
235,477.00CAD+43.96%
163,566.00CAD+51.16%
108,204.00CAD
Access this data via the Eulerpool API

BioSyent Stock analysis

What does BioSyent do? Biosyent Inc is a Canadian pharmaceutical company founded in 2004. The company's headquarters are located in Mississauga, Ontario. Biosyent is listed on the Toronto Stock Exchange and has a market capitalization of approximately 140 million Canadian dollars. The company's business model is based on acquiring domestic pharmaceutical and nutraceutical products and marketing them in Canada. Biosyent operates in two main divisions: Pharma and Nutraceuticals. The Pharma division includes products such as RepaGyn, a vaginal gel for treating dryness and irritation during menopause, as well as the antiemetic Setofilm/Tablets for the prevention and treatment of nausea and vomiting. The Nutraceutical division includes products such as FeraMAX, a supplement that increases iron in the diet and helps prevent the development of anemia. Biosyent also offers vitamin-rich dietary supplements such as Aerobic Oxygen and Calm Biotic, targeting health-conscious customers. Another important area of Biosyent is Hospital Specialty Pharmaceuticals, targeting hospitals and healthcare facilities. This includes products like Cysview and Cysview Kit, used to detect non-muscle invasive bladder cancer and improve fluorescence during cystoscopy. Biosyent also offers infusion sets designed for intravenous medication administration. Overall, Biosyent has more than 20 products in various categories including women's and men's health, ophthalmology, immunology, and oncology. Over the years, Biosyent Inc has received various awards for its products and business practices. In 2012, the company received the Bio-Wellness Award for its flagship product, RepaGyn. While Biosyent has ambitions to expand its presence in international markets, the company remains primarily focused on the Canadian market. Biosyent relies mainly on a low-cost marketing strategy that aims to directly target patients in order to market its products in a simple way. Overall, Biosyent has a strong market position in Canada and a portfolio of well-established products. The company has a successful history and appears ready for the future with a strong pipeline and a growing presence in the Canadian market. BioSyent is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioSyent stock

Stock-Based Compensation (SBC) of BioSyent is 624,613.00 CAD in 2026.

Stock-Based Compensation (SBC) of BioSyent changed from 553,521.00 CAD to 624,613.00 CAD, representing a 12.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) BioSyent since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s BioSyent historically and in real time.

Access this data via the Eulerpool API

Cash Flow — BioSyent

All Key Metrics — BioSyent